MAPT and Alzheimer disease: From a clinical standpoint, the presence of TDP-43 alongside tau in both PART and AD is consistently associated with more severe cognitive impairment and faster rates of cognitive decline, compared to cases with tau or amyloid alone [2,3,14,91,96].